Logo

Amgen and Allergan Report Results of ABP 798 (biosimilar- rituximab) in JASMINE Study for Non-Hodgkin's Lymphoma

Share this
Amgen and Allergan Report Results of ABP 798 (biosimilar- rituximab) in JASMINE Study for Non-Hodgkin's Lymphoma

Amgen and Allergan Report Results of ABP 798 (biosimilar- rituximab) in JASMINE Study for Non-Hodgkin's Lymphoma

Shots:

  • The JASMINE study involves assessing of ABP 798 vs its reference product- Rituximab at a dose of 375 mg/m2 (IV- qw) for 4wks. followed by dosing at weeks 12 and 20 in 256 patients with non-Hodgkin's lymphoma
  • The JASMINE study results demonstrated bio-similarity data in its 1EPs i.e- ORR @28wks. and clinical equivalence to Rituxan. Additionally- the companies conducted a clinical study of ABP 798 in mod. to sev. RA patients resulting in clinical equivalence & pharmacokinetic similarity
  • ABP 798 is an anti-CD20 mAb having the same amino acid sequence as the reference product- Rituxan. In Dec 2011- Amgen and Allergan entered into a WW collaboration to develop & commercialize four oncology antibody biosimilar therapies

Click here to­ read full press release/ article | Ref: Amgen | Image: Behance


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions